Should Renal Inflammation Be Targeted While Treating Hypertension?
Despite extensive research and a plethora of therapeutic options, hypertension continues to be a global burden. Understanding of the pathological roles of known and underexplored cellular and molecular pathways in the development and maintenance of hypertension is critical to advance the field. Immu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2022.886779/full |
| _version_ | 1818211989861695488 |
|---|---|
| author | Sarika Chaudhari Grace S. Pham Calvin D. Brooks Viet Q. Dinh Cassandra M. Young-Stubbs Caroline G. Shimoura Keisa W. Mathis |
| author_facet | Sarika Chaudhari Grace S. Pham Calvin D. Brooks Viet Q. Dinh Cassandra M. Young-Stubbs Caroline G. Shimoura Keisa W. Mathis |
| author_sort | Sarika Chaudhari |
| collection | DOAJ |
| description | Despite extensive research and a plethora of therapeutic options, hypertension continues to be a global burden. Understanding of the pathological roles of known and underexplored cellular and molecular pathways in the development and maintenance of hypertension is critical to advance the field. Immune system overactivation and inflammation in the kidneys are proposed alternative mechanisms of hypertension, and resistant hypertension. Consideration of the pathophysiology of hypertension in chronic inflammatory conditions such as autoimmune diseases, in which patients present with autoimmune-mediated kidney inflammation as well as hypertension, may reveal possible contributors and novel therapeutic targets. In this review, we 1) summarize current therapies used to control blood pressure and their known effects on inflammation; 2) provide evidence on the need to target renal inflammation, specifically, and especially when first-line and combinatory treatment efforts fail; and 3) discuss the efficacy of therapies used to treat autoimmune diseases with a hypertension/renal component. We aim to elucidate the potential of targeting renal inflammation in certain subsets of patients resistant to current therapies. |
| first_indexed | 2024-12-12T05:41:16Z |
| format | Article |
| id | doaj.art-f2cbc185afbf42faa3ae4c0d0c552e1e |
| institution | Directory Open Access Journal |
| issn | 1664-042X |
| language | English |
| last_indexed | 2024-12-12T05:41:16Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Physiology |
| spelling | doaj.art-f2cbc185afbf42faa3ae4c0d0c552e1e2022-12-22T00:35:55ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2022-06-011310.3389/fphys.2022.886779886779Should Renal Inflammation Be Targeted While Treating Hypertension?Sarika ChaudhariGrace S. PhamCalvin D. BrooksViet Q. DinhCassandra M. Young-StubbsCaroline G. ShimouraKeisa W. MathisDespite extensive research and a plethora of therapeutic options, hypertension continues to be a global burden. Understanding of the pathological roles of known and underexplored cellular and molecular pathways in the development and maintenance of hypertension is critical to advance the field. Immune system overactivation and inflammation in the kidneys are proposed alternative mechanisms of hypertension, and resistant hypertension. Consideration of the pathophysiology of hypertension in chronic inflammatory conditions such as autoimmune diseases, in which patients present with autoimmune-mediated kidney inflammation as well as hypertension, may reveal possible contributors and novel therapeutic targets. In this review, we 1) summarize current therapies used to control blood pressure and their known effects on inflammation; 2) provide evidence on the need to target renal inflammation, specifically, and especially when first-line and combinatory treatment efforts fail; and 3) discuss the efficacy of therapies used to treat autoimmune diseases with a hypertension/renal component. We aim to elucidate the potential of targeting renal inflammation in certain subsets of patients resistant to current therapies.https://www.frontiersin.org/articles/10.3389/fphys.2022.886779/fullresistant hypertensionblood pressureimmune cellskidneyautoimmunitysystemic lupus erythematosus |
| spellingShingle | Sarika Chaudhari Grace S. Pham Calvin D. Brooks Viet Q. Dinh Cassandra M. Young-Stubbs Caroline G. Shimoura Keisa W. Mathis Should Renal Inflammation Be Targeted While Treating Hypertension? Frontiers in Physiology resistant hypertension blood pressure immune cells kidney autoimmunity systemic lupus erythematosus |
| title | Should Renal Inflammation Be Targeted While Treating Hypertension? |
| title_full | Should Renal Inflammation Be Targeted While Treating Hypertension? |
| title_fullStr | Should Renal Inflammation Be Targeted While Treating Hypertension? |
| title_full_unstemmed | Should Renal Inflammation Be Targeted While Treating Hypertension? |
| title_short | Should Renal Inflammation Be Targeted While Treating Hypertension? |
| title_sort | should renal inflammation be targeted while treating hypertension |
| topic | resistant hypertension blood pressure immune cells kidney autoimmunity systemic lupus erythematosus |
| url | https://www.frontiersin.org/articles/10.3389/fphys.2022.886779/full |
| work_keys_str_mv | AT sarikachaudhari shouldrenalinflammationbetargetedwhiletreatinghypertension AT gracespham shouldrenalinflammationbetargetedwhiletreatinghypertension AT calvindbrooks shouldrenalinflammationbetargetedwhiletreatinghypertension AT vietqdinh shouldrenalinflammationbetargetedwhiletreatinghypertension AT cassandramyoungstubbs shouldrenalinflammationbetargetedwhiletreatinghypertension AT carolinegshimoura shouldrenalinflammationbetargetedwhiletreatinghypertension AT keisawmathis shouldrenalinflammationbetargetedwhiletreatinghypertension |